Back

Two-year outcomes of dabigatran etexilate treatment in patients with co-morbid heart failure and atrial fibrillation: the GLORIA-AF registry

26 August 2018 (14:00 - 18:00)
Organised by:
Congress Presentation Part of: Poster Session 3 - Atrial fibrillation - Epidemiology prognosis outcome Heart Failure in Atrial Fibrillation ESC Premium Access ESC Congress 2018

About the speaker

Photo
Professor Sergio Jose Dubner

Buenos Aires (Argentina)

9 More presentations in this session

Presentation thumbnail
Doctor B. Kim (Seoul, KR)
Abstract Slides
Presentation thumbnail
Assistant Professor F. Ricci (Chieti, IT)
Abstract Slides
Presentation thumbnail
Professor P. Kirchhof (Hamburg, DE)
Abstract
Presentation thumbnail
Doctor R. Jansen (Alkmaar, NL)
Abstract
Presentation thumbnail
Mr P. Cozzolino (Monza, IT)
Abstract

Access the full session

Session thumbnail
Poster Session 3 - Atrial fibrillation - Epidemiology prognosis outcome

The Event

Event poster

ESC Congress 2018

26 August 2018 14:00 CET
You may be interested in
thumbnail
Congress Presentation
Anticoagulation with direct-acting anticoagulants decreases the risk of cardiovascular adverse events in patients with heart failure and atrial fibrillation compared to acenocoumarol
29 June 2021
thumbnail
Congress Presentation
GLORIA-AF: new Phase III data from this innovative registry program.
28 August 2022
thumbnail
Congress Session
Editor's Choice: report from the heart failure sections of ESC Journal Family and overview of the ESC Textbook of Heart Failure
18 May 2025
thumbnail
Congress Presentation
Association between personalized evidence-based anticoagulation therapy and outcomes at 1-year follow-up in patients with atrial fibrillation: an analysis from the Atrial Fibrillation Registry
29 June 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources